RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
February 03, 2026 13:06 ET | Source: Restem Initiation of the IIMPACT…
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
June 06, 2025 16:07 ET | Source: Restem MIAMI, June 06, 2025…


